ProCE Banner Activity

The Future of CDI Recurrence Prevention?

Clinical Thought

Read my take on why I believe live biotherapeutic products for microbiota restoration following a Clostridioides difficile infection (CDI) are game changers for preventing CDI recurrences.

Released: September 25, 2023

Share

Faculty

Paul Feuerstadt

Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine
Attending Gastroenterologist
Department of Gastroenterology
Yale University School of Medicine
PACT-Gastroenterology Center
Hamden, Connecticut

Provided by

Provided by Clinical Care Options, LLC, in partnership with the Peggy Lillis Foundation.

ProCE Banner

Supporters

Supported by an educational grant from Ferring Pharmaceuticals, Inc.

Ferring Pharmaceuticals, Inc.

Partners

Peggy Lillis Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine
Attending Gastroenterologist
Department of Gastroenterology
Yale University School of Medicine
PACT-Gastroenterology Center
Hamden, Connecticut

Paul Feuerstadt, MD, FACG, AGAF: consultant/advisor/speaker: Ferring, Merck, Sanofi, Seres, Takeda.